KRAS mutant
Quiénes somos
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
Sotorasib y panitumumab frente a la elección del investigador para participantes con sarcoma de rata de Kirsten (KRAS) con mutación p.G12C (CodeBreak 300)
